1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Tecan Group AG

Tecan Group AG

TCGGY
Tecan Group AGUS flagOther OTC
36.00
USD
- -
- -
2.28BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
7.07
7.2
7.78
8.8
9.44
10.12
10.76
12.25
15.49
18
16.83
14.64
13.94
Basic EPS, GAAP
0.83
0.73
1.01
0.95
1.13
1.2
1.24
1.74
1.99
1.91
2.07
1.06
-1.75
Free Cash Flow per Basic Share
0.15
0.46
1.49
1.82
1.37
1.13
1.27
2.8
2.13
1.45
1.97
1.85
1.62
Dividend per Share
0.3
0.3
0.3
0.35
0.35
0.4
0.42
0.44
0.45
0.56
0.58
0.6
0.6
Book Value per Share
6.76
7.02
7.8
8.46
9.34
10.29
11
12.26
14.07
15.46
16.74
17.44
15.48
Tangible Book Value per Share
5.24
4.79
5.82
5.61
6.64
6.87
7.37
8.71
1.43
3.61
5.13
5.73
5.35
Basic Weighted Avg Shares
55
55
57
58
58
59
59
60
61
64
64
64
63
Sales/Revenue/Turnover
388
400
440
506
549
594
637
731
947
1,144
1,074
934
882
Operating Margin (%)
14.11
14.32
15.21
13.46
14.63
14.9
13.91
16.67
15.1
12.92
12.66
8.09
5.44
Depreciation Expense
10
10
16
21
25
22
34
38
59
67
71
67
61
Net Income, GAAP
46
40
57
55
66
71
73
104
122
121
132
68
-111
Effective Tax Rate (%)
17.7
18.17
13.42
16.64
16.54
15.23
11.57
12.3
11.79
14.99
1.29
13.56
- -
Profit Margin (%)
11.76
10.07
12.98
10.77
12.02
11.91
11.49
14.19
12.85
10.59
12.29
7.24
-12.54
Working Capital
282
299
355
393
449
433
458
553
365
467
554
325
423
LT Debt
2
3
4
10
8
1
34
28
301
293
304
60
208
Total Equity
336
361
441
487
550
612
659
734
1,225
1,358
1,349
1,435
1,151
Return on Invested Capital (%)
13.83
12.87
13.78
11.66
12.38
12.51
11.64
14.15
10.71
7.73
7.96
3.76
- -
Return on Capital (%)
12.83
10.5
13.58
11.58
12.62
12.27
11.39
14.24
12.89
9.93
9.97
4.99
- -
Return on Common Equity (%)
12.89
10.58
13.75
11.75
12.81
12.33
11.66
14.99
15.28
13.14
12.88
6.2
-10.57

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.75%
12.76%
-19.78%
Free Cash Flow
8.53%
-6.79%
-12.89%
Net Income, GAAP
-21.76%
-57.27%
-263.53%
Sales/Revenue/Turnover
7.93%
5.14%
-5.54%
Total Cash Common Dividend
8.82%
8.18%
-0.76%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,074
2024
- -
- -
- -
- -
934
2025
- -
- -
- -
- -
882

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.07
2024
- -
- -
- -
- -
1.06
2025
- -
- -
- -
- -
-1.75

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.58
2024
- -
- -
- -
- -
0.6
2025
- -
- -
- -
- -
0.6

Company Description

APIChat
CEO
Monica Manotas
Full Time Employees
3,074
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Address
Seestrasse 103 Männedorf Switzerland 8708
IPO Date
Apr 8, 2022
Website
tecan.com
Similar Companies
Agilent Technologies, Inc. (A)
Puriblood Medical Co., Ltd. (6847.TWO)
bioMérieux S.A. (BMXXY)
Check-Cap Ltd. Ordinary Share (MBAI)
Spermosens AB (SPERM.ST)
CelLBxHealth plc (CLBX.L)
Business
Tecan Group AG (SIX: TECN; OTC: TCGGY) develops, manufactures, and markets automated laboratory instruments, consumables, software, and reagents for life sciences research, diagnostics, and biopharmaceutical applications; its offerings encompass liquid handling and robotics platforms such as the Fluent and Freedom workstations, microplate readers and washers, next-generation sequencing reagents, immunoassay kits, sample preparation solutions including the MagicPrep NGS system, and smart consumables like disposable tips and microplates; additional products include OEM components via Cavro pumps, robots and valves, contract design and manufacturing through Paramit and Synergence services, robotic workcells supported by Director scheduling software, low-volume dispensers like Duo, and multimode readers. The company operates through Life Sciences Business and Partnering Business segments, serving pharmaceutical, biotechnology, academic, clinical diagnostic, and contract development and manufacturing customers in North America, Europe, Asia, and worldwide. Founded in 1980 and headquartered in Männedorf, Switzerland, Tecan has recently expanded its specialty diagnostics portfolio through the April 2025 acquisition of assets related to four ELISA immunoassay kits from Cisbio Bioassays, announced a partnership with Grifols to develop biomarker panels leveraging single molecule counting technology, secured manufacturing contracts with global diagnostics firms via Paramit building on Synergence collaborations, and acquired Wako Automation assets including Director software and hardware modules in December 2025 to bolster robotic workcell capabilities.

Company News

APIChat

  • seekingalpha.com

    Tecan Group AG (TCGGY) Analyst/Investor Day Transcript

  • seekingalpha.com

    Tecan Group AG (TCGGY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q4 2024 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q2 2024 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q4 2023 Earnings Call Transcript

  • seekingalpha.com

    Tecan Group AG (TCHBF) Q2 2023 Earnings Call Transcript